NAGE — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-04

• In July 2026, we publicly introduced NB4168, our proprietary lead investigational therapeutic candidate for the treatment of Ataxia-Telangiectasia (A-T). NB4168 is an oral small molecule engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while mainta…

• In June 2026, we entered into a new office lease for 10,564 rentable square feet in Los Angeles, California. The lease has a contractual term of approximately 8 years and is scheduled to commence on April 1, 2027. We may receive limited early access to the premises prior to the commencement date for…

• In May 2026, we launched a clinician-directed telehealth platform under Niagen Plus, enabling eligible U.S. patients to connect with independent licensed healthcare providers who, where medically appropriate, may prescribe Niagen® at-home injection kits, expanding the Niagen Plus clinic channel beyo…

• In April 2026, we reached an agreement in principle with a retail partner in Asia to resolve a previously disclosed dispute related to the recall and withdrawal of certain Tru Niagen® Immune Daily Defense products.

• Under the terms of the arrangement, previously withheld receivables totaling approximately $1.3 million were released and fully collected by the end of April 2026. We expect this to result in improved collections and a reduction in accounts receivable in the near term.

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• In April 2026, we reached an agreement in principle with a retail partner in Asia to resolve a previously disclosed dispute related to the recall and withdrawal of certain Tru Niagen® Immune Daily Defense products.

• As part of the resolution, previously withheld receivables totaling approximately $1.3 million were released, we received these outstanding balances as of the end of April 2026. We expect this to result in improved collections and a reduction in accounts receivable in the near term.

• The agreement also includes the return of certain unsold inventory and the provision of replacement products. As a result, we expect to recognize costs associated with returned inventory, rework activities, and replacement products, which will be reflected in cost of sales in the period incurred. Th…

• We do not expect the resolution of this matter to have a material adverse impact on our overall financial condition. In addition, while we have agreed to provide replacement products for certain future customer returns of the affected product, such obligations are limited in scope and are not curren…

• Total net sales increased by $1.0 million for the three months ended March 31, 2026, as compared to the same period in 2025. The increase in net sales was attributable to growth within our consumer products and ingredients segments. The pharmaceutical segment did not generate revenue during the peri…

Text added vs the prior filing · source: 10-Q · 2026-08-04

• •increased availability or customer acceptance of alternative ingredients, including NMN, which could cause customers to reduce purchases from us, shift purchases to competing products or seek more favorable pricing or other commercial terms, and any such reduction by a significant customer could di…

• The markets for our products and services are both competitive and price-sensitive. Many of our competitors have significant financial, operations, sales and marketing resources and experience in research and development. Competitors could develop new technologies that compete with our products and …

• •disruptions, suspensions, restrictions or other changes affecting our ability to sell, advertise, fulfill orders or receive payments through third-party e-commerce marketplaces;

• A portion of our consumer product sales depends on third-party e-commerce marketplaces and platforms. Our ability to sell products through these channels depends on our continued compliance with marketplace policies, listing requirements, advertising rules, fulfillment standards, intellectual proper…

• withhold or delay payment of sales proceeds, or take other actions that could adversely affect our sales, cash flows and operating results. Competitors and other third-parties may also challenge our product listings or advertising claims through marketplace complaint, product-compliance or similar p…

Text removed vs the prior filing · source: 10-Q · 2026-05-06

• The markets for our products and services are both competitive and price-sensitive. Many of our competitors have significant financial, operations, sales and marketing resources and experience in research and development. Competitors could develop new technologies that compete with our products and …

• In the ordinary course of our business, we may collect, process, store and transmit proprietary, confidential and sensitive information, including personal information (including health information), intellectual property, trade secrets, and proprietary business information owned or controlled by us…

• interruptions, delays, or outages in our operations, loss of data, loss of income, significant extra expenses to restore data or systems, reputational loss and the diversion of funds. Similarly, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties…

• As part of our business strategy, we may seek to develop partnerships or licensing arrangements to monetize our proprietary molecules for pharmaceutical applications. However, there is no guarantee that we will be able to identify suitable partners, negotiate favorable terms, or successfully execute…

• •we may rely on third-parties to develop and produce our products, which could lead to increased costs, unanticipated delays, or other negative impacts;